Barclays Downgrades Amgen to Underweight, Upgrades Gilead
By Senad Karaahmetovic Barclays analysts downgraded shares of Amgen (NASDAQ:AMGN) to Underweight from Equal Weight with a price target of $234 per share. With Amgen shares up over 20% in...
Strong Buy
or
Gilead News & Analysis
-
-
'Unique Oncology Platform': Gilead Earns Two Upgrades After Beat-and-raise Quarter
By Senad Karaahmetovic Gilead Sciences (NASDAQ:GILD) shares are trading about 5% higher in pre-open trading after the company topped analyst consensus for Q3 and raised its profit...
-
Amazon, Capital One Fall Premarket; Apple, Pinterest, Intel, Exxon Mobil Rise
By Peter Nurse Investing.com -- Stocks in focus in premarket trade on Friday, October 28th. Please refresh for updates. Amazon (NASDAQ:AMZN) stock slumped 12% after the e-commerce giant...
-
Dow Futures Trade Lower, Amazon Tanks 12.7% After Earnings
By Oliver Gray Investing.com - U.S. stock futures fell during Thursday’s evening trade, after major benchmark indices finished the regular session mixed as investors digested a slew of...
-
After-Hours Movers: Amazon Sinks on Lower Guidance, Pinterest Up on Beat
After-Hours Stock Movers: Amazon.com (NASDAQ:AMZN) 14% LOWER; {{erl-6435||reported Q3 EPS of $0.28, $0.06 better than the analyst estimate of $0.22. Revenue for the quarter came in at $127.1...
-
Gilead Sciences Beat Expectations and Raised its Full-Year Outlook
By Liz Moyer Investing.com -- Gilead (GILD) reported third quarter earnings and revenue that topped expectations and it raised its guidance for the full year. The pharmaceutical company...
-
Gilead Sciences Beat Expectations and Raised its Full-Year Outlook
By Liz Moyer Investing.com -- Gilead (NASDAQ:GILD) reported third quarter earnings and revenue that topped expectations and it raised its guidance for the full year. The pharmaceutical...
-
Gilead Sciences Tops Q3 EPS by 38c
Gilead Sciences (GILD) reported Q3 EPS of $1.90, $0.38 better than the analyst estimate of $1.52. Revenue for the quarter came in at $7 billion versus the consensus estimate of $6.13...
-
Gilead Earnings, Revenue beat In Q3
Investing.com - Gilead (NASDAQ:GILD) reported on Thursday third quarter {{erl-6365||earnings that beat analysts' forecasts and revenue that topped expectations. Gilead announced earnings...
-
US Sends Gilead's COVID-19 Antiviral To Safeguard Health Workers In Uganda Ebola Outbreak
The U.S. sent Gilead Sciences Inc's (NASDAQ: GILD) remdesivir and Mapp Biopharmaceutical Inc's experimental Ebola antibody drug MBP134 to Uganda as a response to the Ebola outbreak. The...
-
MacroGenics Teams up with Gilead
Biopharmaceutical company MacroGenics’ (NASDAQ:MGNX) stock is soaring today after it announced a collaboration with Gilead Sciences (NASDAQ:GILD) for the development of bispecific...
-
MacroGenics Shares Jump On Gilead Licensing Pact For Blood Cancer Candidates
Gilead Sciences Inc (NASDAQ: GILD) and MacroGenics Inc (NASDAQ: MGNX) announced an exclusive option and collaboration agreement to develop MGD024 and two additional bispecific research...
-
Gilead's Trodelvy Under FDA Review For Pre-Treated HR+/HER2- Metastatic Breast Cancer
The FDA has accepted for review Gilead Sciences Inc's (NASDAQ: GILD) Trodelvy (sacituzumab govitecan-hziy) for unresectable locally advanced or metastatic hormone receptor (HR) positive,...
-
Today's Most Important Upgrades
By Davit Kirakosyan UBS upgraded Domino's Pizza (NYSE:DPZ) to Buy from Neutral and lowered its price target to $385.00 from $430.00. Shares were trading more than 4% higher intra-day. The...
-
JPMorgan Upgrades Gilead, Says Emerging Oncology Franchise Not Priced In
By Senad Karaahmetovic Shares of Gilead Sciences Inc (NASDAQ:GILD) are up about 3% in pre-open Tuesday after |JPMorgan upgraded to Overweight from Neutral with a price target of $80 per...
-
Gilead Sciences upgraded to overweight from neutral at J.P. Morgan
This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about...
-
Gilead's Investigation Reveals Two Kingpins Directly Associated With Fake HIV Medications Scheme
U.S. District Judge Ann Donnelly has ordered to freeze several assets related to people and entities accused of operating a U.S. supply chain that distributes counterfeit bottles of Gilead...
-
Gilead (NASDAQ: GILD) Ups the Ante Against Counterfeit HIV Drug Ring
Gilead Sciences (NASDAQ: GILD) scored a win against alleged counterfeiters as a federal judge in New York ordered the freezing of assets of different people and entities accused of...
-
WHO Recommends Gilead's COVID-19 Therapy For Severe Disease
Gilead Sciences Inc (NASDAQ: GILD) announced updates to the World Health Organization's (WHO) Therapeutics and COVID-19: living guideline, which now conditionally recommends Veklury...
-
EU regulator recommends extending Gilead's COVID treatment Veklury for use in pediatric patients
Gilead Sciences Inc. said Friday the European regulator has adopted a positive opinion on extending the use of its COVID treatment Veklury for pediatric patients. The European Commission...
-
Coronavirus tally: WHO expands guidelines for Gilead's COVID treatment Veklury
The World Health Organization expanded its recommended guide for the use of Gilead's COVID-19 treatment Veklury late Thursday, adding another treatment to its toolbox. The company said WHO...
-
Gilead COVID-19 drug gets expanded WHO recommendation
Gilead Sciences Inc. said late Thursday the World Health Organization expanded its recommended guide for the use of the biotech drug maker's COVID-19 treatment Veklury. In a statement, the...
-
Gilead Sciences Settlement to Meaningfully Extend Exclusivity of HIV Agents
By Sam Boughedda Gilead Sciences (NASDAQ:GILD) announced Monday that it has entered into agreements with Lupin, Apotex, Macleods Pharma, Hetero Labs, and Cipla to resolve the litigation and...
-
Stocks making the biggest moves midday: Bristol-Myers Squibb, Twitter, Gilead Sciences and more
These are the stocks posting the largest moves midday.
-
Gilead Sciences (NASDAQ:GILD) Ticks Higher After Settling Patent Challenges
Gilead Sciences (NASDAQ:GILD) shares are ticking upwards after the healthcare major disclosed it has resolved litigation and patent challenges with major generic manufacturers including...
-
Gilead's stock jumps 5% after setting patent case related to HIV therapies
Shares of Gilead Sciences Inc. were up 5.2% in premarket trading on Monday after the company said in a securities filing that it settled a patent case that extends the exclusivity of its...
-
Gilead's Trodelvy Shows Improved Overall Survival In Pretreated Breast Cancer Settings
Gilead Sciences Inc (NASDAQ: GILD) announced the overall survival (OS) results from the Phase 3 TROPiCS-02 study of Trodelvy (sacituzumab govitecan-hziy) versus comparator chemotherapy (TPC)...
-
Gilead’s Trodelvy extends breast cancer survival by 3.2 months -study
By Deena Beasley (Reuters) – Gilead Sciences Inc’s Trodelvy extended by 3.2 months the survival of patients with advanced stages of a common type of breast cancer, according to data...
-
Gilead's Breast Cancer Drug Improves Progression-Free Survival in HR+/HER2- Metastatic Breast Cancer
Gilead Sciences Inc (NASDAQ: GILD) outlined new data for the antibody-drug conjugate (ADC) Trodelvy (sacituzumab govitecan-hziy) ahead of their presentation at the European Society of...
-
How Is Gilead (NASDAQ:GILD) Stock Positioned Ahead of ESMO This Week?
Biopharmaceutical behemoth Gilead Sciences (GILD) has reported that new data from a phase 3 study (TROPiCS-02) evaluating Trodelvy against comparator chemotherapies...
-
Stock Market Today: Dow Delivers Swashbuckling Gains as Earnings Shine
By Yasin Ebrahim Investing.com -- The Dow jumped Wednesday, as better-than-expected economic data and mostly positive quarterly results stoked bullish bets on stocks. The Dow Jones...
-
S&P 500 in Rally Mode on Positive Earnings, Stronger Economic Data
By Yasin Ebrahim Investing.com -- The S&P 500 jumped Wednesday, as better-than-expected economic data and mostly positive quarterly results triggered a sea of green on Wall Street. The S&P...
-
Pelosi Riles China, OPEC Meets, and Uber Beats - What's Moving Markets
By Geoffrey Smith Investing.com -- Nancy Pelosi promises the U.S. will not abandon Taiwan. China reacts by ordering a massive four-day live-fire drill immediately off the island's coast....
-
Gilead Sciences Tops Q2 EPS by 6c, Offers Guidance
Gilead Sciences (NASDAQ:GILD) reported Q2 EPS of $1.58, $0.06 better than the analyst estimate of $1.52. Revenue for the quarter came in at $6.3 billion versus the consensus estimate of...
-
Pelosi's Taiwan Visit, JOLTS Survey, Nomad Hack - What's Moving Markets
By Geoffrey Smith Investing.com -- Chinese markets tumble and risk assets struggle as Nancy Pelosi's visit to Taiwan raises the risk of a U.S.-China confrontation. The Labor Department...
-
Dow Futures Ease Following Best Week Since 2020
By Oliver Gray Investing.com - Dow futures were trading slightly lower during Sunday’s evening deals, after major benchmark indices finished this week significantly higher and...
Disclaimer: Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. All CFDs (stocks, indexes, futures), cryptocurrencies, and Forex prices are not provided by exchanges but rather by market makers, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Fusion Media doesn't bear any responsibility for any trading losses you might incur as a result of using this data. Fusion Media or anyone involved with Fusion Media will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible.
